-
OrbiMed Raises Over USD 4.3 Billion for Private Investment Funds Focused on Healthcare
•
US-based investment fund giant OrbiMed has announced the successful raising of over USD 4.3 billion for its latest private investment funds. The capital will be distributed among OrbiMed Private Investments IX, OrbiMed Asia Partners V, and OrbiMed Royalty & Credit Opportunities IV, reflecting the firm’s commitment to expanding its reach…
-
Changchun BCHT Biotechnology Invests in Influenza Vaccine Production Expansion
•
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced plans to invest RMB 805 million (USD 110 million) in the production of 10 million annual doses of its influenza virus split vaccine (BK-01 adjuvant). This substantial investment includes RMB 659 million for industrialization and RMB 146 million for operational…
-
CBC HIP Secures USD 875 Million for Life Science Real Assets Venture CLSRA
•
CBC Healthcare Infrastructure Platform (CBC HIP), a prominent independent life science real assets investor in China, has reportedly closed its second funding round at USD 875 million for its inaugural life science real assets venture, CLSRA Venture I. This significant milestone includes the participation of Abu Dhabi-based sovereign investor Mubadala…
-
Roche’s Q3 2023 Report Shows 1% Global Growth Amid Lower COVID-19 Product Demand
•
Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2023 report, indicating that a reduced demand for COVID-19 products impacted global growth, resulting in a 1% year-on-year (YOY) increase at constant exchange rates over the first nine months, with total sales amounting to CHF 44.1 billion (USD 49.4 billion). Excluding…
-
AlphaGen Therapeutics Secures Seed Funding for Pb-212 Radioligand Therapy Development
•
AlphaGen Therapeutics Ltd, a Shanghai-based developer specializing in radioligand therapy (RLT), has reportedly secured “tens of millions” of US dollars in a seed financing round co-led by Eight Roads. The funds will be instrumental in accelerating the clinical development of the company’s Pb-212 pipeline and in constructing a state-of-the-art radiopharmaceutical…
-
Pharmaron Beijing to Establish Singapore JV Rxilient Biohub for CDMO Services
•
China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) has announced plans to invest USD 10.5 million in establishing a joint venture (JV) named Rxilient Biohub Pte. Ltd. in Singapore. This strategic move marks Pharmaron’s expansion into the Southeast Asian market, aiming to provide…
-
Abbott Reports 8.7% Drop in Q3 2023 Global Sales, Hit by Lower SARS-CoV-2 Test Demand
•
Abbott (NYSE: ABT) published its Q3 2023 financial results this week, reporting a 8.7% year-on-year (YOY) decline in global sales on an organic basis to USD 29.9 billion over the first three quarters. The decrease was primarily attributed to significantly reduced demand for SARS-CoV-2 tests, which led to a 42.1%…
-
J&J Reports Strong Q3 2023 Sales Growth Amid Diverse Business Performance
•
Johnson & Johnson (J&J; NYSE: JNJ) has released its Q3 2023 report, revealing impressive global sales of USD 63.7 billion for the first nine months of the year. This marks a 7.5% year-on-year (YOY) expansion in operational terms, reflecting robust performance across both of the company’s main business segments. Segment…
-
Sirius Therapeutics Secures USD 60 Million in Series B Financing for siRNA Therapy Development
•
Sirius Therapeutics, a Shanghai-based developer of siRNA therapies, has successfully raised USD 60 million in a Series B financing round. This funding is specifically allocated for the clinical development of its siRNA therapy product pipelines and the advancement of next-generation nucleic acid molecular delivery technologies. The financing round was led…
-
EpimAb Biotherapeutics Licenses Bispecific Antibody Platform to Almirall
•
Shanghai-based EpimAb Biotherapeutics has entered into a strategic license agreement with Spanish pharmaceutical company Almirall (BME: ALM) for the development of bispecific antibodies (BsAbs) against up to three undisclosed target pairs. This partnership marks a significant step in leveraging EpimAb’s innovative Fabs-In-Tandem Immunoglobulin (FIT-Ig) platform to generate BsAbs, with Almirall…
-
Suzhou Inhal Pharma Secures Series A Funding for Expansion and Clinical Advances
•
Suzhou Inhal Pharma Co., Ltd, a China-based company dedicated to the research and development of inhalation formulations, inhalers, and filling equipment, has reportedly secured over RMB 50 million (USD 6.8 million) in a Series A financing round. The investment round was spearheaded by Shining Capital, marking a significant boost for…
-
Atom Bioscience Secures $82M Series D to Advance Gout Treatment ABP-671
•
China-based Atom Bioscience, known formally as Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd, has reportedly raised over RMB 600 million (USD 82 million) in a Series D financing round. This follows a GTJA Investment-led Series C financing round in January 2022, which raised RMB 300 million (USD 41 million). The…
-
Shanghai Pharma Health Commerce Secures $68M in Series C Funding Round
•
Shanghai Pharma Health Commerce Co., Ltd, a distinguished former subsidiary of China’s pharmaceutical giant Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607), has reportedly secured RMB 500 million (USD 68 million) in a Series C financing round. This substantial investment underscores the company’s robust growth and potential within the healthcare sector.…
-
Novo Nordisk Reports 33% YOY Sales Increase, Boosts GLP-1 Drug Sales Forecast
•
Denmark-headquartered pharmaceutical giant Novo Nordisk (NYSE: NVO) provided a financial update last week, revealing a robust 33% year-on-year (YOY) increase in sales at constant exchange rates (CER) from Q1 to Q3 this year. Notably, Q3 alone saw a significant 38% YOY jump, indicating a strong market reception for the company’s…
-
Pfizer Adjusts 2023 Revenue Projections Amidst Decreased COVID-19 Solution Demand
•
Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has revised its projected 2023 revenues downward, reflecting a decrease in demand for COVID-19 solutions. The new revenue projection falls between USD 58.0 billion and 61.0 billion, a significant adjustment from the previously anticipated range of USD 67.0 billion to 70.0 billion as reported…
-
Sino Biopharmaceutical Sells 84.2% Stake in Shanghai CP General Pharmaceutical
•
China-based biotech company Sino Biopharmaceutical Ltd (HKG: 1177) has announced the sale of an 84.2% stake in its former subsidiary, Shanghai CP General Pharmaceutical Co., Ltd. This strategic divestiture is expected to generate approximately RMB 290 million (USD 40 million) for the company. Focus on Core Competencies Amid Financial Losses…
-
Shanghai Shende Wuchuang Secures $28 Million in Series D Financing for Medical Device Innovation
•
Shanghai Shende Wuchuang Times Medical Technology Co., Ltd has reportedly secured nearly RMB 200 million (USD 28 million) in a Series D financing round, bringing the company’s total funding to RMB 400 million (USD 56 million). The investors in this round include Zhuji Huiri Yingtian Equity Investment and Hefei Industrial…
-
Hangzhou HealSun Biopharm Secures RMB 200 Million in Series B+ Financing
•
Hangzhou HealSun Biopharm Co., Ltd., a Chinese contract research organization (CRO) and contract development and manufacturing organization (CDMO) specializing in antibodies and recombinant proteins, has successfully raised nearly RMB 200 million (approximately USD 27.8 million) in a Series B+ financing round. The funding was led by China Medical System Holdings…
-
Cardinal Health Acquires MedAlliance for $1.135 Billion to Enhance Vascular Intervention Portfolio
•
US-based Cardinal Health (NYSE: CAH) has announced the acquisition of Swiss firm MedAlliance for a total consideration of USD 1.135 billion. This transaction includes a USD 35 million investment made in 2022, a USD 200 million upfront payment in 2023, and additional regulatory milestone payments totaling USD 125 million, along…
-
Triastek Inc. Secures $20.5 Million in Pre-Series C Financing for 3D Printing Pipeline
•
China-based Triastek Inc., a company at the forefront of pharmaceutical-focused 3D printing, has reportedly secured RMB 150 million (USD 20.5 million) in a pre-Series C financing round. The investment, led by Guoxin Investment, includes participation from Gold Mine Multi-Family Office and Zheng Xiaodong, chairman of Shanghai Tofflon Sci &Tech Co.,…
